Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study clarifies the benefits and risks of treatments for those with multiple myeloma, a blood cancer more common in Black Americans.
Researchers are examining opportunities for immune-modulating approaches to improve outcomes and reduce side effects.
Around 90% of people treated with the immunomodulator did not develop cancer.
Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.
Yolanda Brunson-Sarrabo was diagnosed with smoldering myeloma in 2008.
The proportion of patients receiving treatment has doubled since the early 2000s.
Revlimid improves outcomes for chronic lymphocytic leukemia patients, but better drugs are now available.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.